Pembrolizumab works by blocking a mechanism that cancer cells use to evade detection by the immune system, according to Drugs.com. The U.S. Food and Drug Administration (FDA) first approved it in 2014 ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

A diagnosis of uveal melanoma marks the beginning of a long-term relationship with your medical team. While the focus starts ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and ...

Teddi Mellencamp has shared a sobering update on her health. On April 2, The Real Housewives of Beverly Hills alum said in an emotional Instagram video that she now has stage IV cancer. Mellencamp was ...

Elevated pretreatment levels of LDH and GGT were prognostic for shorter OS in patients with mUM; low albumin, elevated LDH and ALT for shorter TTCS.

MURRAY — Intermountain Medical Center recently became one of the first medical centers in Utah to offer a genetically personalized skin cancer treatment option for those with advanced melanoma.